Chen Hao, Tang Chao, Tan Chun, Wu Fei, Li Zhenhan, Ji Wenyan, Lu Linming, Xu Chongjun, Shen Zhengchao, Huang Yanqiang
Research Center for the Prevention and Treatment of Drug Resistant Microbial Infecting, Youjiang Medical University for Nationalities, Baise 533000, China.
Department of Pathology, Wannan Medical College, Wuhu 241002, China.
J Oncol. 2022 Feb 21;2022:3445350. doi: 10.1155/2022/3445350. eCollection 2022.
. Interleukin-2 (IL-2) is proved to play an irreplaceable role in antitumor regulation in numerous experimental and clinical trials. Tumor-associated macrophages (TAMs) are able to release exosomes to promote the development and progression of hepatocellular carcinoma (HCC) as essential component of microenvironment. In this study, our intention is to explore the effects of the exosomes from TAMs with IL-2 treatment on HCC development. TAMs were collected and cultured from HCC tissues. The exosomes from the TAMs treated with IL-2 (Exo) or not (Exo) were identified and used to treat HCC cells and . The proliferation, apoptosis, and metastasis of HCC cells were measured. The changes of miRNAs in exosomes were explored to clarify the possible mechanisms. Both decrease of cell proliferation and metastasis and increase of apoptosis were observed with Exo treatment compared with Exo and . miR-375 was obviously augmented in Exo and HCC cells treated with Exo. Taken together, IL-2 may modulate exosomal miRNAs from TAMs to ameliorate hepatocellular carcinoma development. This study provides a new perspective to explain the mechanism by which IL-2 inhibits hepatocellular carcinoma and implies the potential clinical value of exosomal miRNAs released by TAMs.
白细胞介素-2（IL-2）在众多实验和临床试验中被证明在抗肿瘤调节中发挥着不可替代的作用。肿瘤相关巨噬细胞（TAM）作为微环境的重要组成部分，能够释放外泌体促进肝细胞癌（HCC）的发生和发展。在本研究中，我们旨在探讨IL-2处理的TAM来源外泌体对HCC发展的影响。从HCC组织中收集并培养TAM。鉴定用或不用IL-2处理的TAM来源的外泌体（Exo），并用于处理HCC细胞。检测HCC细胞的增殖、凋亡和转移情况。探索外泌体中miRNA的变化以阐明可能的机制。与未处理的外泌体（Exo）相比，用处理过的外泌体（Exo）处理后观察到细胞增殖和转移减少以及凋亡增加。在处理过的外泌体（Exo）和用其处理的HCC细胞中miR-375明显增加。综上所述，IL-2可能调节TAM来源的外泌体miRNA以改善肝细胞癌的发展。本研究为解释IL-2抑制肝细胞癌的机制提供了新的视角，并暗示了TAM释放的外泌体miRNA的潜在临床价值。
